genome
Wojcicki, cofounder and former CEO of 23andMe, is set to reacquire the company through her nonprofit, TTAM Research Institute.
The projects will make use of genome sequencing data for more personalized, preventative and cost-effective healthcare.
The company will use the funds to enhance its R&D strategy, advance its SEEDIT platform and boost product development.
The fate of the company's recently-announced research partnerships is unclear.